Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
About this trial
This is an interventional prevention trial for Pulmonary Disease, Chronic Obstructive focused on measuring flow-mediated dilation, arterial stiffness, intima-media thickness, pulse wave velocity, dual energy x-ray absorptiometry, inflammatory markers, blood lipids, tetrahydrobiopterin, body mass index, hemoglobin A1c, complete blood count, oxidative stress biomarkers, pulmonary function test, lung, COPD
Eligibility Criteria
Inclusion Criteria:
- Patients with COPD (GOLD stages II-IV) and matched healthy controls
- Caucasian or African American
- Both men and women
- Current and former smokers
Exclusion Criteria:
- GOLD Stage I
- Clinical diagnosis of heart disease, hypertension, or metabolic disease
- Vasoactive medications (i.e. nitrates, beta-blockers, ACE inhibitors, Viagra, etc.)
- Pulmonary hypertension
- Hypothyroidism
- Hyper-homocysteinemia
- Interstitial lung disease
- Phenylketonuria
- Pregnancy
- Sleep apnea
- Anemia
- Raynod's phenomenon
- Gangrene of the digits
- History of low platelets or coagulopathies
- Aspirin sensitivity or allergy
Sites / Locations
- Augusta University
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
COPD Patients
Controls
Patients with COPD AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)
Healthy age- and sex- matched controls AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)